1
|
Antifouling Strategies of Nanoparticles for Diagnostic and Therapeutic Application: A Systematic Review of the Literature. NANOMATERIALS 2021; 11:nano11030780. [PMID: 33803884 PMCID: PMC8003124 DOI: 10.3390/nano11030780] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 03/12/2021] [Accepted: 03/16/2021] [Indexed: 02/07/2023]
Abstract
Nanoparticles (NPs) are promising platforms for the development of diagnostic and therapeutic tools. One of the main hurdle to their medical application and translation into the clinic is the fact that they accumulate in the spleen and liver due to opsonization and scavenging by the mononuclear phagocyte system. The “protein corona” controls the fate of NPs in vivo and becomes the interface with cells, influencing their physiological response like cellular uptake and targeting efficiency. For these reasons, the surface properties play a pivotal role in fouling and antifouling behavior of particles. Therefore, surface engineering of the nanocarriers is an extremely important issue for the design of useful diagnostic and therapeutic systems. In recent decades, a huge number of studies have proposed and developed different strategies to improve antifouling features and produce NPs as safe and performing as possible. However, it is not always easy to compare the various approaches and understand their advantages and disadvantages in terms of interaction with biological systems. Here, we propose a systematic study of literature with the aim of summarizing current knowledge on promising antifouling coatings to render NPs more biocompatible and performing for diagnostic and therapeutic purposes. Thirty-nine studies from 2009 were included and investigated. Our findings have shown that two main classes of non-fouling materials (i.e., pegylated and zwitterionic) are associated with NPs and their applications are discussed here highlighting pitfalls and challenges to develop biocompatible tools for diagnostic and therapeutic uses. In conclusion, although the complexity of biofouling strategies and the field is still young, the collective data selected in this review indicate that a careful tuning of surface moieties is a pivotal step to lead NPs through their future clinical applications.
Collapse
|
2
|
Heo J, Sobiech TA, Kutscher HL, Chaves L, Sukumaran DK, Karki S, Dube A, Prasad PN, Reynolds JL. Hybrid Curdlan Poly(γ -Glutamic Acid) Nanoassembly for Immune Modulation in Macrophage. Macromol Biosci 2020; 21:e2000358. [PMID: 33283480 DOI: 10.1002/mabi.202000358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 11/12/2020] [Indexed: 11/06/2022]
Abstract
A nanoformulation composed of curdlan, a linear polysaccharide of 1,3-β-linked d-glucose units, hydrogen bonded to poly(γ -glutamic acid) (PGA), was developed to stimulate macrophage. Curdlan/PGA nanoparticles (C-NP) are formulated by physically blending curdlan (0.2 mg mL-1 in 0.4 m NaOH) with PGA (0.8 mg mL-1 ). Forster resonance energy transfer (FRET) analysis demonstrates a heterospecies interpolymer complex formed between curdlan and PGA. The 1 H-NMR spectra display significant peak broadening as well as downfield chemical shifts of the hydroxyl proton resonances of curdlan, indicating potential intermolecular hydrogen bonding interactions. In addition, the cross peaks in 1 H-1 H 2D-NOESY suggest intermolecular associations between the OH-2/OH-4 hydroxyl groups of curdlan and the carboxylic-/amide-groups of PGA via hydrogen bonding. Intracellular uptake of C-NP occurs over time in human monocyte-derived macrophage (MDM). Furthermore, C-NP nanoparticles dose-dependently increase gene expression for TNF-α, IL-6, and IL-8 at 24 h in MDM. C-NP nanoparticles also stimulate the release of IL-lβ, MCP-1, TNF-α, IL-8, IL-12p70, IL-17, IL-18, and IL-23 from MDM. Overall, this is the first demonstration of a simplistic nanoformulation formed by hydrogen bonding between curdlan and PGA that modulates cytokine gene expression and release of cytokines from MDM.
Collapse
Affiliation(s)
- Jeongyun Heo
- Institute for Laser, Photonics and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA.,Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY, 14203, USA
| | - Thomas A Sobiech
- Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA
| | - Hilliard L Kutscher
- Institute for Laser, Photonics and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA.,Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY, 14203, USA.,Department of Anesthesiology, The State University of New York at Buffalo, Buffalo, NY, 14203, USA
| | - Lee Chaves
- Division of Nephrology, Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY, 14203, USA
| | - Dinesh K Sukumaran
- Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA
| | - Shanta Karki
- Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY, 14203, USA
| | - Admire Dube
- School of Pharmacy, University of the Western Cape, Bellville, Cape Town, 7535, South Africa
| | - Paras N Prasad
- Institute for Laser, Photonics and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA.,Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA
| | - Jessica L Reynolds
- Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY, 14203, USA
| |
Collapse
|